Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05722925 · ClinicalTrials.gov registry record · Phase 4

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

A Phase 4 study of Prostate Cancer, sponsored by OHSU Knight Cancer Institute.

Active
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT05722925: Active Phase 4 study of Prostate Cancer, sponsored by OHSU Knight Cancer Institute.

NCT05722925 is a Phase 4 study of Prostate Cancer that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 50 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05722925, a Phase 4 study of Prostate Cancer, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Fluciclovine PET/CT

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-10-04
Est. Completion 2026-12-01
Phase Phase 4
OHSU Knight Cancer Institute

211 total trials

What the registry record for NCT05722925 still lists

NCT05722925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fluciclovine PET/CT is the first listed.

NCT05722925 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT05722925 about?

NCT05722925 is a clinical study titled "Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET". The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help de...

What is the current status of trial NCT05722925?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-10-04. Estimated completion is 2026-12-01.

What conditions does trial NCT05722925 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05722925?

The interventions under investigation include: Fluciclovine PET/CT (DRUG).

Who is sponsoring clinical trial NCT05722925?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05722925 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05722925's enrollment target sits among peer trials

50 469th of 735 higher than 247 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05722925, the US trial registry maintained by the National Library of Medicine. NCT05722925 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.